Research Progress and Perspectives of Antibody-drug Conjugates Targeting Trophoblast Cell Surface Antigen-2 in Advanced Non-small Cell Lung Cancer.
Non-small cell lung cancer (NSCLC) remains a significant global health burden, and there is an urgent need for new treatment options. Trophoblast cell surface antigen-2 (TROP-2), a target closely associated with NSCLC prognosis, has become a research hotspot in recent years. Notably, TROP-2-targeted...
| Publicado en: | Chinese Journal of Lung Cancer Vol. 27; no. 10; pp. 763 - 777 |
|---|---|
| Autores principales: | , , , |
| Formato: | pictorial tables/charts Journal Article |
| Publicado: |
Chinese Journal of Lung Cancer
Oct2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=181422248&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 181422248 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10093419 9014 jtl: Chinese Journal of Lung Cancer issn: 10093419 maglogo: N pubinfo: dt: Oct2024 vid: 27 iid: 10 pid: 54191 pub: Chinese Journal of Lung Cancer artinfo: ui: 181422248 181422248 181422248 10.3779/j.issn.1009-3419.2024.101.25 181422248 ppf: 763 ppct: 14 formats: fmt: @attributes: type: P tig: atl: Research Progress and Perspectives of Antibody-drug Conjugates Targeting Trophoblast Cell Surface Antigen-2 in Advanced Non-small Cell Lung Cancer. aug: au: Jingyan XU Jiaqi LIU Shiqi MEI Qing ZHOU affil: Guangdong Provincial Institute of Lung Cancer, Guangdong Provincial People's Hospital Affiliated to Southern Medical University, Guangdong Academy of Medical Sciences, Guangzhou 510080, China sug: subj: Carcinoma, Non-Small-Cell Lung Drug Therapy Antibodies Pharmacodynamics Antigens, Surface Drug Effects Trophoblasts Drug Effects Carcinoma, Non-Small-Cell Lung Prognosis Clinical Trials Progression-Free Survival Evaluation Mutation Patient Safety Antibodies Adverse Effects Monitoring, Physiologic ab: Non-small cell lung cancer (NSCLC) remains a significant global health burden, and there is an urgent need for new treatment options. Trophoblast cell surface antigen-2 (TROP-2), a target closely associated with NSCLC prognosis, has become a research hotspot in recent years. Notably, TROP-2-targeted antibody-drug conjugates (ADCs) have made groundbreaking advances in NSCLC therapy. Clinical studies have demonstrated that certain TROP-2 ADCs can significantly improve progression-free survival in previously treated patients with advanced or metastatic NSCLC, regardless of the presence of actionable genomic alterations. These agents have shown promising potential in both frontline and subsequent treatment settings. In terms of safety, while adverse effects affecting the hematologic, respiratory, and gastrointestinal systems are generally manageable, close clinical monitoring and timely management are still required. In conclusion, TROP-2 ADCs hold great promise in the treatment of NSCLC. pubtype: Academic Journal doctype: pictorial tables/charts Journal Article ougenre: Article language: Chinese refInfo: holdings: @attributes: islocal: N |
|---|